HDAC6 Identified as Key Driver of Metastasis and Immunosuppression in Small Cell Lung Cancer Study

A recent study has identified HDAC6, a histone deacetylase enzyme, as a significant factor in promoting metastasis and immunosuppression in small cell lung cancer (SCLC). Researchers Jiang, Yu, Wang, and their team conducted the investigation to better understand the mechanisms behind cancer progression and immune system evasion. Their findings highlight HDAC6’s role in driving these processes within SCLC, a highly aggressive form of lung cancer.

The study focused on how HDAC6 contributes to tumor spread and suppresses the body’s immune response against cancer cells. The researchers observed that elevated levels of HDAC6 were associated with increased metastatic activity and reduced immune function in SCLC models. These results suggest that HDAC6 plays a dual role in facilitating both the dissemination of cancer cells to other parts of the body and creating an environment where the immune system is less effective at targeting tumors. The findings provide new insights into potential therapeutic targets for addressing metastasis and immunosuppression in this challenging disease.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: January 24, 2026

Author

GOAI